Absolutely stunning results, more positive data laid upon even more positive data, no adverse effects , MPL making it across the blood brain barrier,,

Would have to make the 2 incumbents look up and take notice...

Riluzole Mitsubishi , $980m per year,, adds approximately 2 to 3 months life extension over a 2.4 to 3 year period from diagnosis.

Pfizer have been active in the ALS/MND Space seeking solutions...

Pfizer buys into Sangamo’s motor neuron disease gene therapy

The pharma giant will pay $12m upfront and $150m in potential milestones

Pfizer is paying $12m upfront to Sangamo Therapeutics in a deal focusing on the development of gene therapies for motor neuron disease, also known as amyotrophic lateral sclerosis (ALS).

The deal - which also includes $150m in potential milestones - focuses on the use of Samgamo’s zinc finger protein (ZFP) technology to address mutations in the C9ORF72 gene, linked to ALS and another neurodegenerative disease called frontotemporal lobar degeneration (FTLD)